- The European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion recommending approval of AbbVie Inc’s (NYSE:ABBV) risankizumab regime for Crohn’s disease.
- The recommendation comes for Skyrizi (600 mg intravenous induction and 360 mg subcutaneous maintenance therapy) for active Crohn’s disease who have had an inadequate response, lost response, or was intolerant to conventional or biologic therapy.
- Related: AbbVie Psoriatic Arthritis Drug Shows Long-term Effect On Skin, Joint Symptoms.
- Three Phase 3 trial data support the backing. Across all three studies, significantly more patients treated with risankizumab achieved the co-primary endpoints of endoscopic response and clinical remission.
- Safety results of risankizumab in Crohn’s disease were consistent with the known safety profile of risankizumab, with no new safety risks observed.
- Price Action: ABBV shares traded lower by 1.16% at $142.39 on the last check Monday.
Morgan Stanley Downgrades TC Energy to Underweight, Announces C$78 Price Target
Morgan Stanley analyst Robert Kad downgrades TC Energy (TSX:TRP) from Equal-Weight to Underweight and announces C$78 price target.
